TransEnterix (NYSEAMERICAN:TRXC) announced its earnings results on Thursday. The medical instruments supplier reported ($0.06) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.07) by $0.01, Briefing.com reports. The business had revenue of $5.40 million for the quarter, compared to the consensus estimate of $5.40 million. The firm’s revenue was up 2850.8% compared to the same quarter last year.
Shares of TRXC opened at $3.22 on Friday. TransEnterix has a 12 month low of $1.27 and a 12 month high of $6.98.
Several research analysts have recently commented on TRXC shares. Zacks Investment Research cut shares of TransEnterix from a “hold” rating to a “sell” rating in a report on Wednesday, July 25th. LADENBURG THALM/SH SH raised shares of TransEnterix from a “neutral” rating to a “buy” rating and set a $5.00 target price on the stock in a report on Friday. Finally, BTIG Research reaffirmed a “hold” rating on shares of TransEnterix in a report on Tuesday, September 25th.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its position in TransEnterix by 467.9% in the second quarter. BlackRock Inc. now owns 9,870,565 shares of the medical instruments supplier’s stock valued at $43,036,000 after buying an additional 8,132,481 shares in the last quarter. Global X Management Co LLC acquired a new stake in TransEnterix in the second quarter valued at approximately $11,212,000. Millennium Management LLC boosted its position in TransEnterix by 787.5% in the first quarter. Millennium Management LLC now owns 1,895,115 shares of the medical instruments supplier’s stock valued at $3,222,000 after buying an additional 1,681,583 shares in the last quarter. UBS Group AG boosted its position in TransEnterix by 1,658.3% in the first quarter. UBS Group AG now owns 906,280 shares of the medical instruments supplier’s stock valued at $1,541,000 after buying an additional 854,737 shares in the last quarter. Finally, Eagle Asset Management Inc. boosted its position in TransEnterix by 152.9% in the second quarter. Eagle Asset Management Inc. now owns 791,165 shares of the medical instruments supplier’s stock valued at $3,449,000 after buying an additional 478,286 shares in the last quarter.
TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.
Recommended Story: How are the companies in the S&P 500 selected?
Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.